Colorectal cancer · 3 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Trifluridine and tipiracil monotherapy Variant #01 | KRAS | R 1 013 418 | 28d | 2.2 mo | 10.3 mo | 3 | R 3 040 255 PFS proxy | 4 |
Regorafenib monotherapy Variant #06 | KRAS | R 307 423 | 28d | 2.2 mo | 10.3 mo | 3 | R 922 268 PFS proxy | 4 |
Sotorasib and Panitumumab Variant #01 Partial | KRAS | R 25 254 | 14d | 4.8 mo | 11.9 mo | 11 | R 277 796 PFS proxy | 4 |
3 of 3 regimens shown